Newswise — A leading expert in pancreatic neuroendocrine cancer from Cedars-Sinai Medical Center is available to answer reporters' questions about the disease that is reported to have claimed the life of Steve Jobs.
Edward M. Wolin, MD, is co-director of the carcinoid and neuroendocrine tumor program at Samuel Oschin Cancer Center. He has one of the nation’s largest practices specializing in pancreatic neuroendocrine cancer. He did not treat nor see Jobs but can authoritatively discuss the disease and newly available treatments for patients fighting it.
To arrange an interview with Dr. Wolin, please call media specialist Nicole White at 310-423-5215 or email at Nicole.firstname.lastname@example.org.
Edward M. Wolin MD
Co-Director, Carcinoid and Neuroendocrine Tumor Program Medical Oncology, Samuel Oschin Cancer Center
Edward M. Wolin, MD, is Co-Director of the Cedars-Sinai Carcinoid and Neuroendocrine Tumor Program. With offices in the Samuel Oschin Comprehensive Cancer Institute, he directs a large patient care and clinical research program, including a weekly Carcinoid/Neuroendocrine Multidisciplinary Patient Management Conference. Dr. Wolin is board certified by the American Board of Internal Medicine with a subspecialty in medical oncology.
His research efforts are directed at finding cancer treatments which are more effective and less toxic. These include clinical trials of pasireotide, lanreotide, everolimus, atiprimod, antibody to IGF-1R, anti-serotonin drugs, anti-angiogenic drugs, targeted radiation, and other novel anti-cancer treatments. Dr. Wolin's research is also directed at development of new imaging and diagnostic procedures for carcinoid/neuroendocrine tumors.
Dr. Wolin has been cited as a "Best Doctor in America" and has been appointed to the advisory board of that organization. He received the Healthnetwork Foundation Service Excellence Award 2009, an annual award to 10 “top physicians in the country”. He is a member of Phi Beta Kappa, Sigma Xi Honorary Scientific Research Society, American Society of Clinical Oncology, American Society of Hematology, North American Neuroendocrine Tumor Society, European Neuroendocrine Tumor Society, Carcinoid Neuroendocrine Tumor Society of Canada, and other professional societies. He is a journal reviewer for the Journal of Clinical Oncology and has authored numerous publications in peer-reviewed journals and book chapters. He presents regularly at major national and international meetings.
Dr. Wolin earned his medical degree at Yale University School of Medicine. He performed his internship, residency and a medical oncology fellowship at Stanford University Medical Center and a clinical fellowship at the National Cancer Institute in Bethesda, MD. Prior to joining Cedars-Sinai, Dr. Wolin was the Director of the Clinical Oncology Program at Washington University in St. Louis, Missouri.